Program
bempedoic acid
Also written as “ETC-1002”, “Bempedoic acid” and “180mg of ETC-1002(bempedoic acid)”.
Its studies are mostly in Hypercholesterolemia · Hyperlipidemias · Dyslipidemias · Coronary Artery Disease · Hyperlipoproteinemia Type II, led by 6 companies.
Drug pageBempedoic acid: every studyMany companies study it; this page follows only the 33 they lead. All 43 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Esperion Therapeutics | 200 open or running | phase 4since Aug 27, 2023 | Dec 16, 2010 | none ahead |
| Daiichi Sankyoits history only | 61 open or running | phase 4since Apr 6, 2025 | Apr 6, 2025 | Jun 1, 2028phase 3 · NCT07474649 |
| Otsukaits history only | 30 open or running | phase 3since Jan 4, 2023 | Mar 2, 2021 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 20 open or running | phase 1since Apr 4, 2025 | Apr 4, 2025 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 3since May 29, 2026 | May 29, 2026 | Jun 30, 2027phase 3 · NCT07623915 |
| Gan & Lee Pharmaceuticalsits history only | 10 open or running | phase 3since Jan 13, 2025 | Jan 13, 2025 | none ahead |
Also a collaborator on its studies: Medpace.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Esperion Therapeutics only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 2 studies since Dec 16, 2010.
- Apr 26, 2012Phase 2 study in HyperlipidemiasNCT01607294 · 60 enrolled · United States
- Dec 14, 20122 phase 2 studies in HypercholesterolemiaNCT01779453, NCT01751984
- Sep 6, 2013Phase 2 study in HypercholesterolemiaNCT01941836 · 349 enrolled · United States
- Feb 24, 2014Phase 2 study in HypercholesterolemiaNCT02072161 · 133 enrolled · United States
- Jun 16, 2014Phase 2 study in HypercholesterolemiaNCT02178098 · 143 enrolled · United States
- Jan 12, 2016Phase 2 study in HyperlipidemiasNCT02659397 · 68 enrolled · United States
- Jan 20, 2016Phase 3 study in HypercholesterolemiaNCT02666664 · 2,230 enrolled · United States, Canada, Germany and more
- Dec 7, 20164 phase 3 studiesNCT02988115, NCT02993406, NCT02991118 and 1 more
- Feb 9, 2017Phase 2 study in HypercholesterolemiaNCT03051100 · 63 enrolled · United States
- Feb 24, 2017Phase 3 study in HypercholesterolemiaNCT03067441 · 1,462 enrolled · United States
- Jun 19, 2017Phase 2 study in HypercholesterolemiaNCT03193047 · 59 enrolled · United States
- Nov 6, 2017Phase 3 study in HyperlipidemiasNCT03337308 · 382 enrolled · United States
- Jan 12, 2023Phase 2 study in HypercholesterolemiaNCT05694260 · 31 enrolled · United States, Canada, Denmark and more
- Aug 27, 2023Phase 4 study in Healthy Lactating WomenNCT06021951 · 16 enrolled · United States
TargetBeta
“An orally bioavailable prodrug and inhibitor of adenosine triphosphate-citrate lyase (ACL), with anti-hyperlipidemic activity”NCIt, by rule
“ATP-citrate synthase inhibitor”ChEMBL 37, by rule
Studies
All 20 Esperion Therapeutics leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06021951Healthy Lactating Women · United States | 4 | Completed | Feb 21, 2024 | 16 |
| NCT05694260Hypercholesterolemia · United States, Canada, Denmark and more | 2 | Completed | Jun 4, 2025 | 31 |
| NCT03337308Hyperlipidemias · United States | 3 | Completed | Jun 18, 2018 | 382 |
| NCT03193047Hypercholesterolemia · United States | 2 | Completed | Jan 29, 2018 | 59 |
| NCT03067441Hypercholesterolemia · United States | 3 | Completed | Nov 5, 2019 | 1,462 |
| NCT03051100Hypercholesterolemia · United States | 2 | Completed | Jun 1, 2017 | 63 |
| NCT03001076Hypercholesterolemia · United States | 3 | Completed | Jan 11, 2018 | 269 |
| NCT02993406Cardiovascular Diseases · United States, Argentina, Australia and more | 3 | Completed | Nov 7, 2022 | 13,970 |
| NCT02991118Hypercholesterolemia · United States | 3 | Completed | Aug 22, 2018 | 779 |
| NCT02988115Hypercholesterolemia · United States, Canada | 3 | Completed | Mar 16, 2018 | 345 |
| NCT02666664Hypercholesterolemia · United States, Canada, Germany and more | 3 | Completed | Feb 21, 2018 | 2,230 |
| NCT02659397Hyperlipidemias · United States | 2 | Completed | Jul 2016 | 68 |
| NCT02178098Hypercholesterolemia · United States | 2 | Completed | May 22, 2015 | 143 |
| NCT02072161Hypercholesterolemia · United States | 2 | Completed | Jan 2015 | 133 |
| NCT01941836Hypercholesterolemia · United States | 2 | Completed | Oct 2014 | 349 |
| NCT01779453Hypercholesterolemia · United States | 2 | Completed | Aug 2013 | 58 |
| NCT01751984Hypercholesterolemia · United States | 2 | Completed | May 1, 2013 | 56 |
| NCT01607294Hyperlipidemias · United States | 2 | Completed | Oct 2012 | 60 |
| NCT01485146Safety Evaluation of Escalating Doses · United States | 1 | Completed | Jan 25, 2012 | 24 |
| NCT01262638Dyslipidemias · United States | 2 | Completed | Aug 23, 2011 | 177 |
How it is read
Names in the registry
- “ETC-1002”, 10 entries
- “Bempedoic acid”, 7 entries
- “180mg of ETC-1002(bempedoic acid)”, 3 entries
- “bempedoic acid”, 3 entries
- “Bempedoic Acid Tablet”, 2 entries
Conditions, from the studies’ own filings
- Hypercholesterolemia, 16 studies
- Hyperlipidemias, 5 studies
- Dyslipidemias, 2 studies
- Coronary Artery Disease, 1 study
- Hyperlipoproteinemia Type II, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.